These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 35247923)
1. A Prospective Observational Study of Active Surveillance in Primary Desmoid Fibromatosis. Colombo C; Fiore M; Grignani G; Tolomeo F; Merlini A; Palassini E; Collini P; Stacchiotti S; Casali PG; Perrone F; Mariani L; Gronchi A Clin Cancer Res; 2022 Sep; 28(18):4027-4032. PubMed ID: 35247923 [TBL] [Abstract][Full Text] [Related]
2. A Nationwide Prospective Clinical Trial on Active Surveillance in Patients With Non-intraabdominal Desmoid-type Fibromatosis: The GRAFITI Trial. Schut AW; Timbergen MJM; van Broekhoven DLM; van Dalen T; van Houdt WJ; Bonenkamp JJ; Sleijfer S; Grunhagen DJ; Verhoef C Ann Surg; 2023 Apr; 277(4):689-696. PubMed ID: 35166264 [TBL] [Abstract][Full Text] [Related]
3. Correlation of CTNNB1 Mutation Status with Progression Arrest Rate in RECIST Progressive Desmoid-Type Fibromatosis Treated with Imatinib: Translational Research Results from a Phase 2 Study of the German Interdisciplinary Sarcoma Group (GISG-01). Kasper B; Gruenwald V; Reichardt P; Bauer S; Hohenberger P; Haller F Ann Surg Oncol; 2016 Jun; 23(6):1924-7. PubMed ID: 26861905 [TBL] [Abstract][Full Text] [Related]
4. CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study. Colombo C; Miceli R; Lazar AJ; Perrone F; Pollock RE; Le Cesne A; Hartgrink HH; Cleton-Jansen AM; Domont J; Bovée JV; Bonvalot S; Lev D; Gronchi A Cancer; 2013 Oct; 119(20):3696-702. PubMed ID: 23913621 [TBL] [Abstract][Full Text] [Related]
5. Lack of Prognostic Value of CTNNB1 Mutation Profile in Desmoid-Type Fibromatosis. Penel N; Bonvalot S; Bimbai AM; Meurgey A; Le Loarer F; Salas S; Piperno-Neumann S; Chevreau C; Boudou-Rouquette P; Dubray-Longeras P; Kurtz JE; Guillemet C; Bompas E; Italiano A; Le Cesne A; Orbach D; Thery J; Le Deley MC; Blay JY; Mir O Clin Cancer Res; 2022 Sep; 28(18):4105-4111. PubMed ID: 35294527 [TBL] [Abstract][Full Text] [Related]
6. Initial Active Surveillance Strategy for Patients with Peripheral Sporadic Primary Desmoid-Type Fibromatosis: A Multicentric Phase II Observational Trial. Bonvalot S; Cozic N; Le Cesne A; Blay JY; Penel N; Fau M; Chevreau C; Anract P; Waast D; Laurence V; Watson S; Duffaud F; Gouin F; Taieb S; Kind M; Lam L Ann Surg Oncol; 2023 Dec; 30(13):8653-8659. PubMed ID: 37777684 [TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of tumor location and gene expression profile in sporadic desmoid tumor. Carrillo-García J; Hindi N; Conceicao M; Sala MÁ; Ugalde A; López-Pousa A; Bagué S; Sevilla I; Vicioso L; Ramos R; Martínez-Trufero J; Gómez Mateo MC; Cruz J; Hernández-León CN; Redondo A; Mendiola M; García JM; Hernández JE; Álvarez R; Agra C; de Juan-Ferré A; Valverde C; Cano JM; Sande LM; Pérez-Fidalgo JA; Lavernia J; Marcilla D; Gutiérrez A; Moura DS; Martín-Broto J Eur J Cancer; 2024 Sep; 209():114270. PubMed ID: 39142211 [TBL] [Abstract][Full Text] [Related]
8. Long-term Outcomes of Oral Vinorelbine in Advanced, Progressive Desmoid Fibromatosis and Influence of Mir O; Honoré C; Chamseddine AN; Dômont J; Dumont SN; Cavalcanti A; Faron M; Rimareix F; Haddag-Miliani L; Le Péchoux C; Levy A; Court C; Briand S; Fadel E; Mercier O; Bayle A; Brunet A; Ngo C; Rouleau E; Adam J; Le Cesne A Clin Cancer Res; 2020 Dec; 26(23):6277-6283. PubMed ID: 32873570 [TBL] [Abstract][Full Text] [Related]
9. Tailored Beta-catenin mutational approach in extra-abdominal sporadic desmoid tumor patients without therapeutic intervention. van Broekhoven DL; Grünhagenl DJ; van Dalen T; van Coevorden F; Bonenkamp HJ; Been LB; Bemelmans MH; Dijkstra SD; Colombo C; Gronchi A; Verhoef C BMC Cancer; 2016 Aug; 16(1):686. PubMed ID: 27565718 [TBL] [Abstract][Full Text] [Related]
10. Prognostic value of CTNNB1 gene mutation in primary sporadic aggressive fibromatosis. van Broekhoven DL; Verhoef C; Grünhagen DJ; van Gorp JM; den Bakker MA; Hinrichs JW; de Voijs CM; van Dalen T Ann Surg Oncol; 2015 May; 22(5):1464-70. PubMed ID: 25341748 [TBL] [Abstract][Full Text] [Related]
11. The Prognostic Role of β-Catenin Mutations in Desmoid-type Fibromatosis Undergoing Resection Only: A Meta-analysis of Individual Patient Data. Timbergen MJM; Colombo C; Renckens M; Kim HS; Rosmalen JV; Salas S; Mullen JT; Colombo P; Nishida Y; Wiemer EAC; Verhoef C; Sleijfer S; Gronchi A; Grünhagen DJ Ann Surg; 2021 Jun; 273(6):1094-1101. PubMed ID: 31804402 [TBL] [Abstract][Full Text] [Related]
12. CTNNB1 S45F mutation predicts poor efficacy of meloxicam treatment for desmoid tumors: a pilot study. Hamada S; Futamura N; Ikuta K; Urakawa H; Kozawa E; Ishiguro N; Nishida Y PLoS One; 2014; 9(5):e96391. PubMed ID: 24788118 [TBL] [Abstract][Full Text] [Related]
13. Does the Addition of Mutations of CTNNB1 S45F to Clinical Factors Allow Prediction of Local Recurrence in Patients With a Desmoid Tumor? A Local Recurrence Risk Model. Pinto FFE; Mello CAL; Nakagawa SA; Chung WT; Torrezan GT; Barros BDF; Cunha IW; Calsavara VF; Carraro DM; Lopes A Clin Orthop Relat Res; 2023 Oct; 481(10):1978-1989. PubMed ID: 37104792 [TBL] [Abstract][Full Text] [Related]
14. Lower Rate of CTNNB1 Mutations and Higher Rate of APC Mutations in Desmoid Fibromatosis of the Breast: A Series of 134 Tumors. Norkowski E; Masliah-Planchon J; Le Guellec S; Trassard M; Courrèges JB; Charron-Barra C; Terrier P; Bonvalot S; Coindre JM; Laé M Am J Surg Pathol; 2020 Sep; 44(9):1266-1273. PubMed ID: 32590455 [TBL] [Abstract][Full Text] [Related]
15. Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in CTNNB1 or APC: A Multi-institutional Retrospective Study. Nathenson MJ; Hu J; Ratan R; Somaiah N; Hsu R; DeMaria PJ; Catoe HW; Pang A; Subhawong TK; Amini B; Sweet K; Feister K; Malik K; Jagannathan J; Braschi-Amirfarzan M; Sheren J; Caldas Y; Moreno Tellez C; Rosenberg AE; Lazar AJ; Maki RG; Benedetto P; Cohen J; Trent JC; Ravi V; Patel S; Wilky BA Clin Cancer Res; 2022 Sep; 28(18):4092-4104. PubMed ID: 35180772 [TBL] [Abstract][Full Text] [Related]
16. Clinical results of active surveillance for extra-abdominal desmoid-type fibromatosis. Sakai T; Nishida Y; Ito K; Ikuta K; Urakawa H; Koike H; Imagama S Cancer Med; 2023 Mar; 12(5):5245-5254. PubMed ID: 36210645 [TBL] [Abstract][Full Text] [Related]
17. β-Catenin in desmoid-type fibromatosis: deep insights into the role of T41A and S45F mutations on protein structure and gene expression. Colombo C; Belfiore A; Paielli N; De Cecco L; Canevari S; Laurini E; Fermeglia M; Pricl S; Verderio P; Bottelli S; Fiore M; Stacchiotti S; Palassini E; Gronchi A; Pilotti S; Perrone F Mol Oncol; 2017 Nov; 11(11):1495-1507. PubMed ID: 28627792 [TBL] [Abstract][Full Text] [Related]
18. Radiation-induced Sarcomas Occurring in Desmoid-type Fibromatosis Are Not Always Derived From the Primary Tumor. Verschoor AJ; Cleton-Jansen AM; Wijers-Koster P; Coffin CM; Lazar AJ; Nout RA; Rubin BP; Gelderblom H; Bovée JV Am J Surg Pathol; 2015 Dec; 39(12):1701-7. PubMed ID: 26414222 [TBL] [Abstract][Full Text] [Related]
19. β-Catenin mutation status and outcomes in sporadic desmoid tumors. Mullen JT; DeLaney TF; Rosenberg AE; Le L; Iafrate AJ; Kobayashi W; Szymonifka J; Yeap BY; Chen YL; Harmon DC; Choy E; Yoon SS; Raskin KA; Hornicek FJ; Nielsen GP Oncologist; 2013; 18(9):1043-9. PubMed ID: 23960186 [TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical staining with non-phospho β-catenin as a diagnostic and prognostic tool of COX-2 inhibitor therapy for patients with extra-peritoneal desmoid-type fibromatosis. Sakai T; Nishida Y; Hamada S; Koike H; Ikuta K; Ota T; Ishiguro N Diagn Pathol; 2017 Aug; 12(1):66. PubMed ID: 28851389 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]